The world is full of extraordinary individuals that come from every walk of life. No matter the skin complexion, these individuals have done some amazing things to better society. Unfortunately, people like this tend to get overlooked even though they’ve brought so much to the table. Society tends to celebrate professional athletes and entertainers on a regular basis. Dr. Clay Siegall just so happens to be one of these extraordinary figures. He has taken a small startup business and have turned it into a worldwide juggernaut. This company is known as Seattle Genetics, and it has revolutionized the medical industry.
Siegall is the chief financial officer, the president and one of the founders of Seattle Genetics. He has studied at the University of Maryland as well as studied at George Washington University. These two higher learning institutions have awarded him with a Ph.D in Genetics as well as a B.S. in Zoology. Siegall specializes in fighting cancer, and he does this via antibody-based therapies. These therapies are actually antibody drug conjugates, and they are some of the best cancer eradicating medications in the history of mankind. They aggressively attack cancer cells without harming any of the good cells. This is innovation at its finest. Being so great, these antibody drug conjugates are now being used in 65 foreign countries. This comes from Siegall’s ability to strike many different licensing deals with high profile companies. The medications are so successful to where they have helped Seattle Genetics grow at a dramatic rate. The company’s stock has tripled in just five short years.
Siegall’s strong passion and determination has turned him into a fan favorite in a sense. This philanthropist has won many philanthropic awards including the Pacific Northwest Ernst & Young Entrepreneur of the Year as well as the 2013 University of Maryland Alumnus of the Year for Computer, Math & Science.
Dr. Clay Siegall is the co-founder and the current President of Seattle Genetics. He enjoys many of experience in cancer-related medical services. He has a great passion for giving better treatment options to cancer patients by focusing on drugs that will and are supporting the patients. As the company’s CEO and chairman of Directors Board, he has been able to focus on developing various antibody-based cancer therapies.
Seattle Genetics was established in 1997. Today, Clay Siegall has transformed the company to a medical powerhouse in cancer research space. He sets enormous targets and plans for the company whereby the company has increased its drug varieties in recent years. Seattle Genetics has been able to create and sell their drugs through a professional sales team that has medical treatment understanding. The Company also generates revenues by licensing their invented methods and procedures to other companies.
He envisions that the world needs better solutions other than the common cancer therapies that have been done on patients. He points out that his passion for specializing in cancer research and treatment came when he lost a close family member to cancer. He strongly believes that the relative succumbed due to harsh chemotherapy, he was subjected to. Dr. Siegall has the vision to create better ways to treat cancer patients. He targets to improve cancer therapies come up with more effective drugs.
Dr. Siegall holds a degree in Bachelor of Science in zoology from the University of Maryland, and a Ph.D. in Genetics awarded at George Washington University. Apart from establishing Seattle Genetics, he has worked with various organizations in his career life. In 1991, he worked as a senior researcher at Bristol-Myers Pharmaceutical where he was later appointed as a Principal Scientist until the end of 1997. He became the CEO of Seattle Genetics in 2000 before taking over as its President. He also serves as one of the directors of Alder Biopharmaceuticals and also serves on the Board of Governors at the Fred Hutchinson Cancer Research Business Alliance.
Siegall’s efforts to control cancer have seen him receive various recognitions. Due to his undertakings in the area of targeted toxins was recognized and presented with the Pierce Award in 1995. In 2002, he was named the Ernst and Young Pacific Northwest Entrepreneur of the Year grant finalist in the medical category.